Story
Tech Stock Positioning Normalizes as Investors Rotate Out, Deutsche Bank Says
Summary
Investor positioning in large-cap technology stocks has fallen from extended levels to near neutral, according to Deutsche Bank, which notes the rotation out of the sector is about three-quarters complete.
Investor positioning in large-cap technology stocks has dropped sharply from previously extended levels to near neutral, with a rotation out of the sector now roughly three-quarters complete, according to a new report from Deutsche Bank.
The analysis, led by strategist Parag Thatte, indicates that the move away from tech contributed to a broader decline in overall equity positioning last week.
Broader Shift in Equity Exposure
A key divergence emerged between different investor types. Discretionary investor positioning fell sharply to below neutral levels, while systematic strategies reduced their exposure but maintained an overall overweight stance, according to the bank's research.
Within systematic strategies, the report noted:
- Volatility control funds trimmed their equity allocation but remained overweight.
- Commodity Trading Advisors (CTAs) slightly lowered their equity positions but stayed in the upper end of their recent range.
AdContrasting Global Fund Flows
The report also highlighted significant cross-currents in global fund flows, which painted a complex picture of investor sentiment. Despite the repositioning in the U.S., global equity funds attracted substantial inflows of $30.4 billion.
However, this was driven almost entirely by Asia, which saw $21.3 billion in new capital. In contrast, U.S. equity funds recorded outflows of $7.2 billion.
Meanwhile, bond funds received $14.9 billion in inflows, marking a three-month low. Money market funds posted outflows of $33.9 billion for the second consecutive week, suggesting some cash is being deployed back into the markets.
Read next
More on Stocks
Oura IPO Sees Strong Demand, Orders Outpace Shares Four-to-One
Smart ring maker Oura Inc. is seeing robust investor interest in its initial public offering, with orders reportedly reaching four times the number of available shares as it seeks to raise up to $2.2 billion.
Mirum Pharmaceuticals Gains FDA Approval for Rare Bone Disease Drug Atebrioz
The U.S. FDA has approved Mirum's Atebrioz (zilurgisertib), a new oral therapy for treating Fibrodysplasia Ossificans Progressiva (FOP), a severe genetic bone disorder, in patients 12 and older.
S&P Downgrades Cable One to 'B+' on Mounting Competitive Pressures
S&P Global Ratings has lowered Cable One's credit rating to 'B+' from 'BB-', citing intense competition from fiber and fixed wireless services that is eroding its financial performance. The company remains on a negative credit watch, signaling the potential for another downgrade following its planned acquisition of MBI.
Brinker International Upgraded to Ba1 by Moody's on Chili's Strength and Debt Reduction
Moody's raised its rating on the parent company of Chili's and Maggiano's, citing strong operational momentum and successful deleveraging, while maintaining a stable outlook.